# Regeneron Pharmaceuticals

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/regeneron-pharmaceuticals/

## Facts

| Field | Value |
| --- | --- |
| Country | US |
| Description | American pharmaceutical company |
| OpenAlex ID | https://openalex.org/F4320311600 |
| ROR ID | https://ror.org/02f51rf24 |
| Works | 11,917 |

## Funder papers

Showing 15 of 22.

- [Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity](https://scholariq.org/papers/effect-of-continued-weekly-subcutaneous-semaglutide-vs-placebo-on-weight-loss/)
- [Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes](https://scholariq.org/papers/concurrent-rb1-and-tp53-alterations-define-a-subset-of-egfr-mutant-lung-cancers/)
- [Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction](https://scholariq.org/papers/efficacy-of-dapagliflozin-on-renal-function-and-outcomes-in-patients-with-heart/)
- [Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus/)
- [Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial](https://scholariq.org/papers/niraparib-first-line-maintenance-therapy-in-patients-with-newly-diagnosed/)
- [Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF](https://scholariq.org/papers/initial-decline-dip-in-estimated-glomerular-filtration-rate-after-initiation-of/)
- [Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers](https://scholariq.org/papers/molecular-biomarkers-of-disease-outcomes-and-mechanisms-of-acquired-resistance/)
- [Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial](https://scholariq.org/papers/effect-of-empagliflozin-on-heart-failure-outcomes-after-acute-myocardial/)
- [Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial](https://scholariq.org/papers/effects-of-empagliflozin-on-progression-of-chronic-kidney-disease-a-prespecified/)
- [Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment](https://scholariq.org/papers/economic-burden-of-adult-patients-with-moderate-to-severe-atopic-dermatitis/)
- [Atopic Dermatitis in US Adults: From Population to Health Care Utilization](https://scholariq.org/papers/atopic-dermatitis-in-us-adults-from-population-to-health-care-utilization/)
- [Insights From Caregivers on the Impact of Pediatric Atopic Dermatitis on Families: “I’m Tired, Overwhelmed, and Feel Like I’m Failing as a Mother”](https://scholariq.org/papers/insights-from-caregivers-on-the-impact-of-pediatric-atopic-dermatitis-on/)
- [Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database](https://scholariq.org/papers/costs-and-treatment-patterns-among-patients-with-atopic-dermatitis-using/)
- [Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy](https://scholariq.org/papers/small-cell-transformation-in-egfr-mutated-non-small-cell-lung-cancer-dll3/)
- [Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study](https://scholariq.org/papers/long-term-effectiveness-of-dupilumab-in-patients-with-atopic-dermatitis-results/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.